Pharsight

Drugs that contain Enasidenib Mesylate

1. Drug name - IDHIFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9512107 CELGENE CORP Therapeutically active compositions and their methods of use
Jan, 2033

(10 years from now)

US10093654 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9738625 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9732062 CELGENE CORP Therapeutically active compounds and their methods of use
Sep, 2034

(11 years from now)

CN105916507A CELGENE CORP Therapy Active Compound And Using Method Thereof
Jan, 2020

(2 years ago)

CN108912066B CELGENE CORP Treating Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

CN104114543A CELGENE CORP Therapy Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

CN107417667A CELGENE CORP Therapy Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

CN107417667B CELGENE CORP Therapeutically Active Compounds And Methods Of Use Thereof
Jan, 2033

(10 years from now)

CN104114543B CELGENE CORP Therapeutically Active Compound And Its Using Method
Jan, 2033

(10 years from now)

CN108912066A CELGENE CORP A Therapeutically Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

EP3406608A1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3406608B8 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2800743A1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2800743B1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3406608B1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2800743A4 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3566706A1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Aug, 2034

(11 years from now)

EP3566706B1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Aug, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 CELGENE CORP Methods and compositions for cell-proliferation-related disorders Jun, 2030

(7 years from now)

US10294215 CELGENE CORP Therapeutically active compounds and their methods of use Jan, 2033

(10 years from now)

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.